Program
Interferon beta-1a
Also written as “Rebif®”, “RNF” and “Rebif”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.
Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 230 open or running | phase 4since Sep 13, 2005 | Dec 15, 2004 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 210 open or running | phase 4since Feb 23, 2004 | Feb 23, 2004 | none ahead |
| Faron Pharmaceuticalsits history only | 30 open or running | phase 3since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| Biocadits history only | 20 open or running | phase 3since May 29, 2015 | Jan 10, 2013 | none ahead |
| Cinnagen | 20 open or running | phase 3since Jan 17, 2022 | Jul 14, 2018 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 13, 2009 | Nov 13, 2009 | none ahead |
| Trio Medicinesits history only | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Cinnagen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2018First study: phase 1 study in BioequivalenceFirst studyNCT03614715 · 40 enrolled · Finland
- Jan 17, 2022Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT05242133 · 168 enrolled · Iran, Islamic Republic of
TargetBeta
“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Studies
All 2 Cinnagen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05242133Multiple Sclerosis, Relapsing-Remitting · Iran, Islamic Republic of | 3 | Completed | Apr 27, 2022 | 168 |
| NCT03614715Bioequivalence · Finland | 1 | Completed | Feb 12, 2019 | 40 |
How it is read
Names in the registry
- “Interferon beta-1a”, 11 entries
- “Rebif®”, 7 entries
- “RNF”, 5 entries
- “Rebif”, 4 entries
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 21 studies
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- COVID-19, 3 studies
- Colitis, Ulcerative, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.